181 related articles for article (PubMed ID: 9815816)
1. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion.
Hedlund TE; Moffatt KA; Uskokovic MR; Miller GJ
Clin Cancer Res; 1997 Aug; 3(8):1331-8. PubMed ID: 9815816
[TBL] [Abstract][Full Text] [Related]
2. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
3. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
[TBL] [Abstract][Full Text] [Related]
5. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
Moffatt KA; Johannes WU; Miller GJ
Clin Cancer Res; 1999 Mar; 5(3):695-703. PubMed ID: 10100724
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3.
Shabahang M; Buras RR; Davoodi F; Schumaker LM; Nauta RJ; Uskokovic MR; Brenner RV; Evans SR
Cancer Res; 1994 Aug; 54(15):4057-64. PubMed ID: 8033137
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, 1alpha,25-dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalcifero l (Ro 25-6760), on a human colon cancer xenograft.
Evans SR; Schwartz AM; Shchepotin EI; Uskokovic M; Shchepotin IB
Clin Cancer Res; 1998 Nov; 4(11):2869-76. PubMed ID: 9829754
[TBL] [Abstract][Full Text] [Related]
8. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3.
Murthy S; Marcelli M; Weigel NL
Prostate; 2003 Sep; 56(4):293-304. PubMed ID: 12858358
[TBL] [Abstract][Full Text] [Related]
9. The anti-proliferative effect of vitamin D3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity.
Nayeri S; Danielsson C; Kahlen JP; Schräder M; Mathiasen IS; Binderup L; Carlberg C
Oncogene; 1995 Nov; 11(9):1853-8. PubMed ID: 7478614
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
11. The first locked side-chain analogues of calcitriol (1alpha,25-dihydroxyvitamin D3) induce vitamin D receptor transcriptional activity.
Pérez-García X; Rumbo A; Larriba MJ; Ordóñez P; Muñoz A; Mouriño A
Org Lett; 2003 Oct; 5(22):4033-6. PubMed ID: 14572242
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
Bauer JA; Thompson TA; Church DR; Ariazi EA; Wilding G
Prostate; 2003 May; 55(3):159-67. PubMed ID: 12692781
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
Golovko O; Nazarova N; Tuohimaa P
Life Sci; 2005 Jun; 77(5):562-77. PubMed ID: 15904673
[TBL] [Abstract][Full Text] [Related]
14. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
15. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Bao BY; Hu YC; Ting HJ; Lee YF
Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
[TBL] [Abstract][Full Text] [Related]
16. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
17. 24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.
Shiohara M; Uskokovic M; Hisatake J; Hisatake Y; Koike K; Komiyama A; Koeffler HP
Cancer Res; 2001 Apr; 61(8):3361-8. PubMed ID: 11309293
[TBL] [Abstract][Full Text] [Related]
18. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
19. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.
Schwartz GG; Oeler TA; Uskoković MR; Bahnson RR
Anticancer Res; 1994; 14(3A):1077-81. PubMed ID: 8074453
[TBL] [Abstract][Full Text] [Related]
20. 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells.
Schwartz GG; Wang MH; Zang M; Singh RK; Siegal GP
Cancer Epidemiol Biomarkers Prev; 1997 Sep; 6(9):727-32. PubMed ID: 9298581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
